---
title: "Tianxing Medical Surges Over 192% on Hong Kong Debut"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285141013.md"
description: "Tianxing Medicalhad a remarkable debut on the Hong Kong Stock Exchange, opening at HKD 288, a rise of over 192% from its IPO price of HKD 98.5. This strong performance indicates significant investor interest and confidence in the company's market potential, as reported by Jin10."
datetime: "2026-05-05T01:24:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285141013.md)
  - [en](https://longbridge.com/en/news/285141013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285141013.md)
generator: "portal-rs"
---

# Tianxing Medical Surges Over 192% on Hong Kong Debut

Tianxing Medical (01609.HK) made a strong debut on the Hong Kong Stock Exchange, opening at HKD 288, which marks an increase of over 192% from its initial public offering price of HKD 98.5. According to Jin10, the company's impressive performance on its first trading day reflects strong investor interest and confidence in its market potential.

### Related Stocks

- [01609.HK](https://longbridge.com/en/quote/01609.HK.md)

## Related News & Research

- [Star Sports Medicine Wins EU MDR and Overseas Device Approvals](https://longbridge.com/en/news/298519713.md)
- [Star Sports Medicine files HKEX next-day return disclosing share buyback at HKD 111.87 per share](https://longbridge.com/en/news/298583688.md)
- [Lifecare Boosts Majority Stake in Ocean TuniCell with New Share Issue](https://longbridge.com/en/news/298763508.md)
- [Embodied AI startup PHYMI raises nearly US$100 million in seed funding](https://longbridge.com/en/news/298548201.md)
- [Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer](https://longbridge.com/en/news/298830338.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**